CancerNetwork Members: Login | Register
 

 
NEWS
Multiple Myeloma: To T or Not to T, What Will the Answer Be?
www.hematology.org - 11/4/11
The Future of Treatment for Patients With Relapsed/Refractory Multiple Myeloma - Cancer Network
www.cancernetwork.com - 11/7/11
Light Chain-Associated Renal Disorders
emedicine.medscape.com - 12/5/11
 
PRACTICE GUIDELINES
National Guideline Clearinghouse | Multiple myeloma (MM).
www.guidelines.gov -
National Guideline Clearinghouse | Bortezomib in multiple myeloma and lymphoma.
www.guidelines.gov -
National Guideline Clearinghouse | American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.
www.guidelines.gov -
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs
 
GUIDELINES

NCCN guideline on multiple myeloma


 

National Guidelines Clearinghouse

Other society guidelines on multiple myeloma
 
CONTINUING MEDICAL EDUCATION
 
OTHER RESOURCES

National Cancer Institute PDQ: Multiple Myeloma and Other Plasma Cell Neoplasms Treatment

 

Multiple Myeloma page from Oncology STAT

 

Open Multiple Myeloma Studies from Clinical Trials.gov

 

Meeting Abstracts
ASCO
ASH

 

Order Your Copy!
(2010, 13th Edition)

 


 

Please allow 3 – 4 weeks to ship
 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Sign up for our
Newsletters
Subscribe to our
RSS Feed

Multiple Myeloma
 
LATEST FEATURES
December 16, 2011
Oncologic Emergencies and Paraneoplastic Syndromes
Superior vena cava syndrome (SVCS) is a common occurrence in cancer patients and can lead to life-threatening complications such as cerebral or laryngeal edema. More »
November 30, 2011
Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) is the IV infusion of hematopoietic stem and progenitor cells designed to establish marrow and immune function in patients with a variety of acquired and inherited malignant and nonmalignant disorders. More »
November 9, 2011
Multiple Myeloma and Other Plasma Cell Dyscrasias
Multiple myeloma is a disseminated malignancy of monoclonal plasma cells that accounts for 15% of all hematologic cancers. In 2010, an estimated 20,180 new cases will be diagnosed in the United States, and 10,650 Americans will die of this disease. More »
November 7, 2011
Current Advances in Non–Proteasome Inhibitor–Based Approaches to the Treatment of Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) remains incurable despite the current approaches used in initial therapy, including more effective induction therapy, one or more autologous stem-cell transplants, and consolidation/maintenance strategies. More »
November 7, 2011
Multiple Myeloma: A Clinical Overview
Multiple myeloma (MM) is a malignant, progressive plasma cell tumor characterized by overproduction of monoclonal immunoglobulins, osteolytic bone lesions, renal disease, and immunodeficiency.[1] Before the 1980s, patients with MM experienced a slow, progressive decline in quality of life until death approximately 2 years after diagnosis. More »
Showing 1 - 5 of 396 results.
Page of 80
First Previous Last
 
MEDLINE
Shear flow-induced formation of tubular cell protrusions in multiple myeloma cells.
pubmed.gov - 12/1/11
Exposure of live cells to shear flow induces major changes in cell shape, adhesion to the extracellular matrix, and migration. In the present study, we show that exposure of cultured multiple myeloma (MM) cells to shear flow of 4-36dynes/cm(2) triggers the extension of long tubular protrusions (denoted flow-induced protrusions, or FLIPs) in the direction of the flow. These FLIPs were found to be rich in actin, contain few or no microtubules and, apart from endoplasmic reticulum (ER)-like membranal structures, are devoid of organelles. Studying the dynamics of this process revealed that FLIPs elongate at their tips in a shear force-dependent manner, and retract at their bases. Examination of this force dependence revealed considerable heterogeneity in the mechanosensitivity of individual cells, most likely reflecting the diversity of the malignant B cell population. The mechanisms underlying FLIP formation following mechanical perturbation, and their relevance to the cellular
Searching for antigen epitope specificities in the monoclonal IgG molecules of patients with multiple myeloma. The description of a monoclonal antibody with a dynein-specific antigen epitope character.
pubmed.gov - 10/1/11
Metatarsal stress fractures in patients with multiple myeloma treated with long-term bisphosphonates: a report of six cases.
pubmed.gov - 9/21/11
Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications.
pubmed.gov - 10/1/11
Patients with multiple myeloma undergoing autologous haemopoietic stem cell transplantation (ASCT) are at high risk for infectious complications. Peri-transplant intravenous immunoglobulin (IVIG) has been used with the aim of reducing these risks. Our retrospective, non-randomised study of peri-transplant IVIG use and effect on infectious complications in 266 ASCTs for myeloma from 2000 to 2009 at a major metropolitan referral centre for haematological malignancies found no difference between those receiving peri-transplant IVIG (0.4 g/kg) (n=130) and those who were not (n=110) with regard to bloodstream infections, pneumonia, urinary tract or gastrointestinal infections. When analysed according to pre-transplant therapy (conventional chemotherapy versus novel agents), there was no significant difference in infectious complications between those who did or did not receive peri-transplant IVIG. In conclusion, our study did not show a benefit for the use of peri-transplant IVIG (0.4 g/kg
Thirteenth biannual report of the Cochrane Haematological Malignancies Group--focus on multiple myeloma.
pubmed.gov - 9/7/11
 
CLINICAL TRIALS
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma - Full Text View - ClinicalTr
www.clinicaltrials.gov -
An Investigational Drug, PD 0332991, Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
A Study of Mircera in Anemic Patients With Multiple Myeloma - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-Reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Autologous Transplantation for Multiple Myeloma - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
 
MULTIPLE MYELOMA

Here you'll find new developments in the management of multiple myeloma.

 

What will be the best use of new immunomodulatory agents such as thalidomide and bortezomib? Which new genetic or clinical markers will emerge to improve risk stratification for multiple myeloma?          

 

With offerings from a diversity of authoritative online resources, this is the best place to remain up to date with rapid changes in science and clinical practice that affect multiple myeloma management.
 



 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 
 
FROM PHYSICIANS PRACTICE
Tax Schemes Every Physician Should Avoid
Ike Devji, JD, January 31, 2012
The next 60 days marks the final push to sell physicians across the United States tax plans of both good and questionable value.
Boosting Collections at Your Medical Practice: Whose Job Is It?
P.J. Cloud-Moulds, January 28, 2012
Embrace the relationship between your billing company and your medical practice staff.
Managing Difficult Medical Practice Employees
Shelly K. Schwartz, January 27, 2012
Tips for transforming immature staff members into great employees.
Prevent Physician Distraction When Using mHealth Technology
Aubrey Westgate, January 25, 2012
As more and more physicians use handheld mobile technology in their day-to-day work, some critics are raising concerns about “distracted doctoring.”
Can That Applicant Do the Job at Your Medical Practice?
Karen Zupko, January 25, 2012
If like many communities, yours has significant numbers of non-English speaking people with whom neither you nor your staff are able to converse, your practice is at a serious disadvantage.
 
MOST POPULAR
 
COMMENTS